Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07160179 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT07160179 is a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy that is actively recruiting participants, run by AbbVie. The registered enrollment target is 66 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT07160179, a Phase 1 study of Age-related Macular Degeneration and Geographic Atrophy, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration ABBV-6628 is an investigational monoclonal antibody fragment being developed for the treatment of geographic atrophy (GA) secondary to (AMD) age-related macular degeneration. Participants in the Stage 1 part will be placed in 1 of 4 groups, called treatment arms. Participants in Stage 2 will be placed into 1 of 2 groups. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis GA secondary to age-related macular degeneration will be enrolled. Around 66 participants will be enrolled in the study at approximately 27 sites across the US. Participants in Stage 1 will be given ABBV-6628 as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection) with dose escalation. Participants in Stage 2 will receive ABBV-6628 or SYFOVRE, an approved treatment for geographic atrophy, administered as per the FDA-approved label. The treatment duration is approximately 22 months and 3 months of follow-up. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG ABBV-6628
- DRUG SYFOVRE
Study Locations (4)
Texas
- Retina Research Institute of Texas /ID# 262141 - Abilene
- Retina Foundation of the Southwest /ID# 262479 - Dallas
- Retina Consultants - The Woodlands /ID# 262138 - The Woodlands
Indiana
- Retina Partners Midwest, P.C. /ID# 262172 - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2029-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07160179
The ClinicalTrials.gov registry entry for NCT07160179 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (96% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which ABBV-6628 is the first listed.
NCT07160179 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Texas, Indiana.
Frequently Asked Questions
What is clinical trial NCT07160179 about?
NCT07160179 is a clinical study titled "Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 ...
What is the current status of trial NCT07160179?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2025-08-13. Estimated completion is 2029-10.
What conditions does trial NCT07160179 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration, Geographic Atrophy.
What interventions are being tested in trial NCT07160179?
The interventions under investigation include: ABBV-6628 (DRUG), SYFOVRE (DRUG).
Who is sponsoring clinical trial NCT07160179?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07160179 being conducted?
This trial has 4 study locations across Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.